Hemostemix files FDA pre-submission for multi-indication stem cell trial
Tweet Send to a Friend
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) submitted FDA Pre-IND Application 1517 seeking regulatory feedback on a basket protocol Phase I ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
